Predict your next investment

Venture Capital
elsalifescience.com

See what CB Insights has to offer

Investments

11

Portfolio Exits

2

About Eckert Life Science Accelerator

Eckert Life Science Accelerator (ELSA), a spin-off of Eckert Wagniskapital und Fruhphasenfinanzierung, is a Berlin-based life science incubator with over two decades of experience in the venture capital industry. ELSA invests primarily in start-up companies who are in need of first-round venture capital financing and actively supports them during the transformation process from start-ups into mature and valuable companies. The Eckert & Ziegler AG and the Glycotope GmbH are the two most renowned and successful co-foundings and investments.

Eckert Life Science Accelerator Headquarter Location

Robert-Rossle-Str. 10

Berlin, 13125,

Germany

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Eckert Life Science Accelerator News

Myelo Therapeutics Closes Financing Round and Gains Strong Backing of Eckert & Ziegler Group

Jun 29, 2020

Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing therapies for cancer supportive care and medical countermeasures (MCM), announced today the successful closing of a multi-million Euro financing round, following the recent award of a large development contract from the US National Institute of Allergy and Infectious Diseases (NIAID), to develop the orally applied, clinical-stage new chemical entity Myelo001 as an MCM for the treatment of Hematopoietic Acute Radiation Syndrome (H-ARS). The financing round was led by venture capital investor Eckert Life Science Accelerator (ELSA), along with other Myelo Therapeutics shareholders. It will fund Myelo001 through multiple development and regulatory inflection points of its cancer supportive care and MCM indications. Upon successfully closing the financing round, Myelo Therapeutics shareholder Eckert & Ziegler Group further increased its shareholdings in Myelo Therapeutics. The Eckert & Ziegler Group is one of the world’s largest providers of isotope technology for medical, scientific, and industrial use. The company focuses on applications in cancer therapy, industrial radiometry, and nuclear imaging. “Our investors see a clear unmet medical need in the cancer supportive care and radiation countermeasure indications that Myelo001 addresses. This has been re-confirmed by the decision of the US National Institutes of Health to award a development contract to Myelo001,” states Till Erdmann, Managing Director and Chief Business Officer of Myelo Therapeutics. “Given their business activities in cancer therapy and track record in commercial pharma and as a US government supplier, our shareholders will continue to provide strategic guidance as Myelo Therapeutics investors.” Myelo001 is a clinical-stage adjuvant cancer therapy for the treatment of chemotherapy- and radiotherapy-induced myelosuppression. It is delivered as an oral tablet formulation and is stable at room temperature for at least 3 years. Preclinical and clinical studies have shown that Myelo001 has both prophylactic and therapeutic efficacy at reducing hematopoietic symptoms caused by radiation and chemotherapy. In irradiated mice and rabbits, Myelo001 reduced the nadir and accelerated recovery of neutrophils, lymphocytes, thrombocytes, and erythrocytes. In mice, treatment 24 hours post-total body irradiation resulted in increased survival, faster bone marrow recovery, and reduced body weight loss. Moreover, Myelo001 treatment prior to chemotherapy led to a faster recovery of blood cells in human subjects. Comprehensive chronic toxicology and safety studies, as well as clinical studies, have confirmed Myelo001’s excellent safety profile. About Myelo Therapeutics: Myelo Therapeutics is a pharmaceutical company based in Berlin, Germany, that is developing innovative treatments in areas of high unmet medical needs, such as Chemotherapy-induced Myelosuppression (CIM), Radiation-induced Myelosuppression (RIM), and Acute Radiation Syndrome (ARS). For more information, visit www.myelotherapeutics.com .

Eckert Life Science Accelerator Investments

11 Investments

Eckert Life Science Accelerator has made 11 investments. Their latest investment was in Myelo Therapeutics as part of their Series C on June 6, 2020.

CBI Logo

Eckert Life Science Accelerator Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/29/2020

Series C

Myelo Therapeutics

No

1

2/6/2020

Series A

PentixaPharm

$16.46M

Yes

1

10/12/2017

Seed VC

iRT Systems

Yes

1

12/15/2015

Series B

Subscribe to see more

Subscribe to see more

10

9/25/2013

Series A

Subscribe to see more

Subscribe to see more

10

Date

6/29/2020

2/6/2020

10/12/2017

12/15/2015

9/25/2013

Round

Series C

Series A

Seed VC

Series B

Series A

Company

Myelo Therapeutics

PentixaPharm

iRT Systems

Subscribe to see more

Subscribe to see more

Amount

$16.46M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

Eckert Life Science Accelerator Portfolio Exits

2 Portfolio Exits

Eckert Life Science Accelerator has 2 portfolio exits. Their latest portfolio exit was PentixaPharm on April 16, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/16/2021

Corporate Majority

$99M

1

5/19/2015

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/16/2021

5/19/2015

Exit

Corporate Majority

Acquired

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

1

10

Eckert Life Science Accelerator Team

1 Team Member

Eckert Life Science Accelerator has 1 team member, including current Managing Partner, Andreas Eckert.

Name

Work History

Title

Status

Andreas Eckert

Managing Partner

Current

Name

Andreas Eckert

Work History

Title

Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.